17 Sep 2018 12:55
Abzena plc
Result of Annual General Meeting
Cambridge, UK, 17 September 2018: Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, announces that at its Annual General Meeting held today at 10:00am at the offices of Pinsent Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES, all resolutions were duly passed.
Details of the votes received in relation to each of the resolutions are as follows:
Resol
| Vote For | % In favour | Votes Against | % Against | Votes Abstain | % Abstain | Total Votes |
1 | 122,288,284 | 100 | 0 | 0 | 0 | 0 | 122,288,284 |
2 | 122,288,284 | 100 | 0 | 0 | 0 | 0 | 122,288,284 |
3 | 122,288,284 | 100 | 0 | 0 | 0 | 0 | 122,288,284 |
4 | 122,288,284 | 100 | 0 | 0 | 0 | 0 | 122,288,284 |
5 | 122,288,284 | 100 | 0 | 0 | 0 | 0 | 122,288,284 |
6 | 122,288,284 | 100 | 0 | 0 | 0 | 0 | 122,288,284 |
7 | 122,288,284 | 100 | 0 | 0 | 0 | 0 | 122,288,284 |
8 | 122,288,284 | 100 | 0 | 0 | 0 | 0 | 122,288,284 |
Percentage figures have been subject to rounding as considered appropriate.
The total number of ordinary shares of £0.002 each eligible to be voted at the Annual General Meeting was 214,220,399.
Enquiries:
Abzena Plc John Burt (Chief Executive Officer) Julian Smith (Chief Financial Officer) | +44 1223 903498 |
|
|
N+1 Singer (Nominated Adviser and Broker) Aubrey Powell Ben Farrow
| +44 20 7496 3000 |
Instinctif Partners Melanie Toyne SewellRozi MorrisAlex Shaw | +44 20 7457 2020 abzena@instinctif.com |
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENA Inside products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
· Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;
· Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
· Cell line development for the manufacture of recombinant proteins and antibodies;
· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
· Proprietary site-specific conjugation technologies and novel payloads for ADC development;
· GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and
· GMP analytical services for biopharmaceutical manufacturing projects.
For more information, please see www.abzena.com.